Year None202120202019201820172016 Date Latest Press Release December 17, 2018 Eiger Announces Breakthrough Therapy Designation Granted by FDA for Lonafarnib for Treatment of Hepatitis Delta Virus (HDV) Infection December 11, 2018 Eiger BioPharmaceuticals Reports on 2018 R&D Day December 4, 2018 Eiger BioPharmaceuticals to Host R&D Day in New York City December 3, 2018 Eiger BioPharmaceuticals Announces the Appointment of Sri Ryali as Chief Financial Officer December 3, 2018 Eiger BioPharmaceuticals Announces FDA Acceptance of IND Application for Lonafarnib for the Treatment of Progeria and Progeroid Laminopathies November 19, 2018 Eiger to Participate in Piper Jaffray Healthcare Conference November 9, 2018 Eiger Bio Reports Third Quarter 2018 Financial Results October 23, 2018 Eiger BioPharmaceuticals Prices Previously Announced Public Offering of Common Stock October 22, 2018 Eiger BioPharmaceuticals Announces Proposed Public Offering of Common Stock October 22, 2018 Eiger BioPharmaceuticals Receives FDA Rare Pediatric Disease (RPD) Designation for Lonafarnib for the Treatment of Progeria and Progeroid Laminopathies and Plans NDA Filing in 2019 Pagination First page « first Previous page ‹ previous … Page 5 Page 6 Page 7 Page 8 Current page 9 Page 10 Page 11 Page 12 Page 13 … Next page next › Last page last »
